CClinicalTrials.gg
Not yet recruitingNCT07828691Updated Sep 18, 2026

18F-FDG PET/CT for Diagnosis of Diabetic Foot Osteomyelitis

An observational study in Diabetic Foot Infections, sponsored by Jewish General Hospital. Not yet recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Jewish General Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

Diabetic foot osteomyelitis (DFO) is a bone infection of the foot that can occur in people with diabetes and may lead to serious complications, including amputation. Diagnosing DFO can be difficult. This prospective multicenter observational study will evaluate how accurately 18F-FDG PET/CT can diagnose DFO in patients who are already referred for this imaging test as part of their clinical care. The study will use current-generation digital PET/CT systems and standardized interpretation criteria. PET/CT findings will be compared with bone biopsy results when available, or with clinical and imaging findings obtained during at least 6 months of follow-up.

02

Conditions studied

  • Diabetic Foot Infections

Browse trials for

Keywords

  • FDG, PET/CT, diabetic feet, osteomyeltis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with diabetes and suspected diabetic foot infection with concern for osteomyelitis who have been referred by their treating physician for 18F-FDG PET/CT at participating academic centers in Canada and the United States. Approximately 150 consecutive eligible participants will be prospectively enrolled. Clinical care, including the decision to perform bone biopsy or other investigations and treatments, will remain at the discretion of the treating physicians.

Inclusion criteria

Age ≥18 years Diagnosis of diabetes mellitus Referred by the treating physician for clinically indicated 18F-FDG PET/CT of the foot for diabetic foot infection with concern for possible osteomyelitis

Exclusion criteria

Exclusion Criteria:

History of previous bone infection in the study foot within the past 6 months Congenital bone disease such as osteogenesis imperfecta Active pregnancy Recent surgery in the foot with suspected osteomyelitis within the past 6 months Inability to provide informed consent or undergo PET/CT imaging

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with suspected diabetic foot osteomyelitis

    Adults with diabetes and suspected diabetic foot infection with concern for osteomyelitis who are referred by their treating physician for 18F-FDG PET/CT. Participants will undergo standard clinical care and will be followed through medical record review for at least 6 months to establish the final diagnosis and clinical outcomes.

    Diagnostic Test: 18F-FDG PET/CT

Interventions

  • Diagnostic test18F-FDG PET/CT

    18F-FDG PET/CT of the feet performed using current-generation digital PET/CT systems and a standardized acquisition protocol. PET/CT images will subsequently be evaluated using standardized interpretation criteria to determine diagnostic performance for diabetic foot osteomyelitis.

05

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of 18F-FDG PET/CT for diabetic foot osteomyelitis

    Diagnostic performance of 18F-FDG PET/CT for diabetic foot osteomyelitis will be assessed by calculating sensitivity, specificity, positive predictive value, and negative predictive value. PET/CT findings will be compared with a reference standard consisting of histopathology from bone biopsy when available, unequivocal cortical erosion/destruction on CT, or clinical and radiographic/CT confirmation during follow-up.

    Time frame: At least 6 months after PET/CT

06

Study locations

4 sites
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Hôpital du Sacré-Cœur de Montréal
    Montreal, Canada
  • Jewish General Hospital
    Montreal, Canada
  • McGill University Health Centre
    Montreal, Canada
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07828691
Lead sponsor
Jewish General Hospital
Collaborators
Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mars Shot Research Fund
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Sep 18, 2026

Study contacts

Gad Abikhzer, MD
Contact
gad.abikhzer@mcgill.ca
514-340-8222
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion